Jeffrey Ryan  Stewart net worth and biography

Jeffrey Stewart Biography and Net Worth

EVP of AbbVie
Jeffrey R. Stewart is Executive Vice President, Chief Commercial Officer. He is responsible for leading the largest commercial area for the enterprise encompassing multiple therapeutic areas across immunology, oncology, virology, eye care, neuroscience, endo-metabolics, gastroenterology, specialty products and women’s health.

Mr. Stewart joined Abbott in 1992 as part of TAP, Abbott’s former U.S. joint venture with Takeda Chemical Industries. Following his time with TAP, Mr. Stewart held various leadership positions in Abbott’s U.S. and international pharmaceutical businesses, including Divisional Vice President, Immunology; Divisional Vice President, Primary Care; General Manager, Virology; and General Manager, United Kingdom. Prior to AbbVie's separation from Abbott in January 2013, Mr. Stewart served as Vice President, Abbott Proprietary Pharmaceutical Division, United States.

Mr. Stewart previously led the U.S. Area for 10 years, including most recently as Senior Vice President, U.S. Commercial Operations.
Mr. Stewart previously served on the Board of the National Pharmaceutical Council and serves on the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). At AbbVie, he is the executive chair of the PRIDE Employee Resource Group.

What is Jeffrey Ryan Stewart's net worth?

The estimated net worth of Jeffrey Ryan Stewart is at least $10.14 million as of March 18th, 2024. Mr. Stewart owns 60,941 shares of AbbVie stock worth more than $10,141,801 as of May 19th. This net worth approximation does not reflect any other assets that Mr. Stewart may own. Additionally, Mr. Stewart receives an annual salary of $4,320,000.00 as EVP at AbbVie. Learn More about Jeffrey Ryan Stewart's net worth.

How old is Jeffrey Ryan Stewart?

Mr. Stewart is currently 55 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 70 years old. Learn More on Jeffrey Ryan Stewart's age.

What is Jeffrey Ryan Stewart's salary?

As the EVP of AbbVie Inc., Mr. Stewart earns $4,320,000.00 per year. There are 2 executives that earn more than Mr. Stewart. The highest earning executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who commands a salary of $7,190,000.00 per year. Learn More on Jeffrey Ryan Stewart's salary.

How do I contact Jeffrey Ryan Stewart?

The corporate mailing address for Mr. Stewart and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Jeffrey Ryan Stewart's contact information.

Has Jeffrey Ryan Stewart been buying or selling shares of AbbVie?

Jeffrey Ryan Stewart has not been actively trading shares of AbbVie in the last ninety days. Most recently, Jeffrey Ryan Stewart sold 58,949 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $178.79, for a transaction totalling $10,539,491.71. Following the completion of the sale, the executive vice president now directly owns 60,941 shares of the company's stock, valued at $10,895,641.39. Learn More on Jeffrey Ryan Stewart's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Jeffrey Ryan Stewart Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2024Sell58,949$178.79$10,539,491.7160,941View SEC Filing Icon  
3/13/2023Sell53,125$152.28$8,089,875.0060,941View SEC Filing Icon  
3/24/2022Sell27,690$159.20$4,408,248.00View SEC Filing Icon  
12/15/2021Sell2,152$128.00$275,456.00View SEC Filing Icon  
12/29/2020Sell25,290$105.00$2,655,450.0076,259View SEC Filing Icon  
5/12/2020Sell23,024$90.00$2,072,160.0052,760View SEC Filing Icon  
8/16/2019Buy15,552$64.44$1,002,170.8865,304View SEC Filing Icon  
See Full Table

Jeffrey Ryan Stewart Buying and Selling Activity at AbbVie

This chart shows Jeffrey Ryan Stewart's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $166.42
Low: $164.49
High: $166.49

50 Day Range

MA: $169.88
Low: $159.62
High: $182.10

2 Week Range

Now: $166.42
Low: $130.96
High: $182.89

Volume

5,152,176 shs

Average Volume

5,284,928 shs

Market Capitalization

$293.88 billion

P/E Ratio

49.38

Dividend Yield

3.73%

Beta

0.61